Alectinib companion diagnostic - Foundation Medicine
Alternative Names: Alectinib-FoundationOne® CDx - Foundation MedicineLatest Information Update: 10 Jun 2026
At a glance
- Originator Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer
- Registered Solid tumours
Most Recent Events
- 09 Mar 2026 Registered for Solid tumours (Diagnosis) in Japan (unspecified route)
- 19 Sep 2024 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route) before September 2024 (Foundation Medicine website, September 2024)
- 30 Oct 2020 Registered for Non-small cell lung cancer (Diagnosis) in USA